LCL-161
- Generic Name
- LCL-161
- Drug Type
- Small Molecule
- Chemical Formula
- C26H33FN4O3S
- CAS Number
- 1005342-46-0
- Unique Ingredient Identifier
- 6TNS415Y3P
- Background
LCL161 has been used in trials studying the treatment of Leukemia, Neoplasms, Solid Tumors, Breast Cancer, and Ovarian Cancer, among others.
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT03111992
- Locations
- ๐บ๐ธ
Mayo Clinic Arizona, Phoenix, Arizona, United States
๐บ๐ธSarah Cannon Research Institute, Nashville, Tennessee, United States
๐ช๐ธNovartis Investigative Site, Madrid, Spain
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
- Conditions
- Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 298
- Registration Number
- NCT02890069
- Locations
- ๐บ๐ธ
Huntsman Cancer Institute, Salt Lake City, Utah, United States
๐ฌ๐งNovartis Investigative Site, Oxford, United Kingdom
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
- Conditions
- Small Cell Lung CancerOvarian Cancer
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT02649673
- Locations
- ๐บ๐ธ
Florida Cancer Specialists-Sarasota, Sarasota, Florida, United States
๐บ๐ธOklahoma University Health Science Center/Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
๐บ๐ธTennessee Oncology PLLC, Nashville, Tennessee, United States
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
- Conditions
- Primary MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis PhaseSecondary Myelofibrosis
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT02098161
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors
- First Posted Date
- 2013-10-24
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT01968915
- Locations
- ๐ฏ๐ต
Novartis Investigative Site, Kobe-city, Hyogo, Japan
SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological StudyOther: Quality-of-Life Assessment
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 25
- Registration Number
- NCT01955434
- Locations
- ๐บ๐ธ
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
๐บ๐ธMayo Clinic in Florida, Jacksonville, Florida, United States
๐บ๐ธMayo Clinic, Rochester, Minnesota, United States
Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 24
- Registration Number
- NCT01934634
- Locations
- ๐บ๐ธ
2 Sites, incl Tyler, TX and Dallas, TX, Texas, United States
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 209
- Registration Number
- NCT01617668
- Locations
- ๐บ๐ธ
Stanford University Medical Center Stanford, Stanford, California, United States
๐บ๐ธVanderbilt University Medical Center Vanderbilt - Thompson Ln, Nashville, Tennessee, United States
๐บ๐ธHighlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 76
- Registration Number
- NCT01240655
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute SC, Boston, Massachusetts, United States
๐บ๐ธUniversity of North Carolina Lineberger Comp Cancer Ctr, Chapel Hill, North Carolina, United States
๐ช๐ธNovartis Investigative Site, Barcelona, Catalunya, Spain
Safety and Efficacy of LCL161 in Patients With Solid Tumors
- First Posted Date
- 2010-04-05
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 71
- Registration Number
- NCT01098838
- Locations
- ๐บ๐ธ
UNC/ Lineberger Comprehensive Cancer Center Dept. of LinbergerCancerCtr(2), Chapel Hill, North Carolina, United States
๐บ๐ธSarah Cannon Research Institute DeptofSarahCannonRes.Inst. (2), Nashville, Tennessee, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.